Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Fig 2
Comparisons of the ATB (+) and ATB (-) groups in terms of PFS (a) based on mRECIST and (b) based on RECIST v1.1. Abbreviations: ATB, antibiotics; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; mRECIST, modified RECIST; PFS, progression-free survival.